Chlordecone exposure and prostate cancer in Martinique

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational case-control study enrolling men newly diagnosed with prostate cancer and biopsy-negative control men identified over a three-year period in Martinique. Investigators will compare histories and measures of chlordecone and other pesticide exposure between cases and controls, and adjust for known risk factors such as age, family history, and ethnicity. Participants are adult men under 75 who have lived in Martinique for at least six months and are treated at local hospitals and clinics. Clinical data and biological samples will be collected through participating centers including the University Hospital of Martinique and Clinique Saint‑Paul.

Why it matters

Who can join: the full rules

INCLUSION CRITERIA

To take part in this research, participants must meet the following criteria:

Patients/cases :

* All men newly diagnosed with Prostate Cancer in Martinique during a three-year given period in all public and private services caring for patients with Prostate Cancer, identified via multidisciplinary consultation meetings.
* Male adults under 75 years of age
* Resident in Martinique for at least 6 months
* Histologically confirmed (inclusion possible as soon as the result is known by the urologist)
* Affiliated to a social security scheme or equivalent
* Have signed a free and informed consent form

Biopsy-negative" controls (Group 1 controls):

* All men with a negative prostate biopsy following elevated Prostate Specific Antigen (PSA) assay (\> 2.5 ng/ml) within a 3-year period in all public and private services in Martinique identified via urologists or pathologists.
* Male adults under 75 years of age
* Resident in Martinique for at least 6 months
* Frequency matched on age (+/- 5 years) to patients
* Affiliated to a social security scheme or equivalent
* Signed free and informed consent

PSA-negative" controls (Group 2 controls):

* All men with a PSA ⩽ 2.5 ng/ml within a 3-year period and less than 3 months identified via a survey institute
* Male adults under 75 years of age
* Resident in Martinique for at least 6 months
* Frequency matched on age (+/- 5 years) against patients
* Frequency matched on socio-professional category against men of the same age in Martinique (INSEE data)

NON INCLUSION CRITERIA

To take part in this research, participants must not meet the following criteria:

* Be subject to a legal protection measure (safeguard of justice, curatorship or guardianship).
* Inability to consent because does not speak French or Creole.

Where it's running

• University Hospital of Martinique (CHUM)
  Fort-de-France, Martinique Recruiting
• The private clinic "Clinique Saint-Paul"
  Fort-de-France, Martinique Not yet recruiting

Study contacts

• Study coordinator: Florence MENEGAUX, MD, PhD
• Email: florence.menegaux@inserm.fr
• Phone: +33 1 45 59 51 53

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.